Compare Cerus Corp. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 346 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.15
-26.06%
5.63
Revenue and Profits:
Net Sales:
58 Million
(Quarterly Results - Dec 2025)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.0%
0%
-20.0%
6 Months
32.31%
0%
32.31%
1 Year
20.28%
0%
20.28%
2 Years
-7.53%
0%
-7.53%
3 Years
-41.3%
0%
-41.3%
4 Years
-69.56%
0%
-69.56%
5 Years
-70.99%
0%
-70.99%
Cerus Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
17.17%
EBIT Growth (5y)
8.89%
EBIT to Interest (avg)
-11.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.12
Sales to Capital Employed (avg)
1.25
Tax Ratio
1.09%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
79.79%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.63
EV to EBIT
-9.79
EV to EBITDA
-10.40
EV to Capital Employed
5.04
EV to Sales
1.78
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-51.47%
ROE (Latest)
-26.06%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 30 Schemes (29.15%)
Foreign Institutions
Held by 45 Foreign Institutions (11.3%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
57.80
50.80
13.78%
Operating Profit (PBDIT) excl Other Income
-6.40
-6.30
-1.59%
Interest
2.00
2.10
-4.76%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.20
-2.60
15.38%
Operating Profit Margin (Excl OI)
-129.30%
-145.50%
1.62%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is 13.78% vs 8.55% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is 15.38% vs -85.71% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
206.10
180.30
14.31%
Operating Profit (PBDIT) excl Other Income
-34.30
-33.30
-3.00%
Interest
8.30
8.90
-6.74%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-15.60
-21.00
25.71%
Operating Profit Margin (Excl OI)
-176.30%
-195.70%
1.94%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.31% vs 15.28% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 25.71% vs 44.15% in Dec 2024
About Cerus Corp. 
Cerus Corp.
Pharmaceuticals & Biotechnology
Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.
Company Coordinates 
Company Details
1220 Concord Ave Ste 600 , CONCORD CA : 94520-4906
Registrar Details






